Articles from Hope Biosciences

For millions of people living with the long-term effects of traumatic brain injury (TBI), the prevailing belief has been that chronic neuroinflammation causes recovery to plateau over time, meaning correspondingly few long-range care options.

Enrollment has opened at UTHealth San Antonio for a 51-participant, FDA-authorized double-blind placebo-controlled Phase II clinical trial to evaluate if intravenously infused Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) affect brain structure, neurocognitive and functional outcomes, and/or neuroinflammation after traumatic brain injury (TBI) in adults.

FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric clinical trial, to evaluate if intravenous infusion affects signs and symptoms of oligoarticular or polyarticular juvenile idiopathic arthritis (JIA) and improve quality of life in suffering children aged 2 – 16 years old.

Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for treatment of patients living with relapsing-remitting multiple sclerosis (RRMS), based on research conducted by Sugar Land-based non-profit clinical research organization Hope Biosciences Research Foundation (HBRF).

A four-year, nearly $5 million clinical trial grant awarded to UTHealth Houston by the Department of Defense’s Office of Congressionally Directed Medical Research Programs (CDMRP) will evaluate if intravenously infused Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce chronic neuroinflammatory response to severe traumatic brain injury (TBI).